EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rate and Characteristics of Metformin Use in Gestational Diabetes

Thanachot Techawijittra iD, Dittakarn Boriboonhirunsarn iD

Obstetrics and Gynecology International · 2026-01 · 2026 (1)

DOI: 10.1155/ogi/1243724 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obstetrics and Gynecology International, online erschienen am 23.08.2026. Verfasst von Thanachot Techawijittra und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, mahidol.ac.th. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To determine the rate and characteristics of metformin use in the treatment of gestational diabetes mellitus (GDM).

Methods

A total of 286 pregnant women diagnosed with GDM at a university‐based tertiary care hospital were included. In addition to nutritional therapy, the decision regarding metformin use was at the physicians’ discretion. Data were retrieved from medical records, including baseline obstetric characteristics, GDM diagnosis, dosage and formulation of metformin, insulin requirement, and pregnancy outcomes. The rate of metformin use was estimated, and factors associated with metformin use were evaluated.

Results

The mean age was 33.8 years, 55.9% were nulliparous, and 43.4% were overweight or obese. Mean gestational age at diagnosis was 18.7 weeks, and 57% were diagnosed before 20 weeks. Metformin was used in 16.1%, with an initial dosage of 500–1000 mg/d in 95.7%. The final dosage was > 1000–2000 mg/d in 43.5%. A dosage increment was required in 50%. Insulin therapy was needed in 13% of those who received metformin. Metformin use significantly increased in those with obesity, high 50‐g glucose challenge test results, and abnormal fasting plasma glucose (FPG) at diagnosis. Logistic regression analysis showed that the only factors that significantly increased the use of metformin therapy were obesity (adjusted OR: 2.88, 95% CI: 1.17–7.07, p = 0.021) and abnormal FPG at diagnosis (adjusted OR: 5.06, 95% CI: 2.21–11.57, p < 0.001). Maternal and neonatal outcomes were comparable between those with and without metformin use.

Conclusion

Metformin was used in 16.1% of women with GDM. Significant associated factors were obesity and abnormal FPG at diagnosis.

Schlagwörter

Stichwörter der Autor:innen

dosagegestational diabetes mellitusglycemic controlmetformin

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, mahidol.ac.th.

ORCID-Profile: Thanachot Techawijittra, Dittakarn Boriboonhirunsarn

Zitieren

APA

Techawijittra, T., & Boriboonhirunsarn, D. (2026). Rate and Characteristics of Metformin Use in Gestational Diabetes. Obstetrics and Gynecology International, 2026(1). https://doi.org/10.1155/ogi/1243724

Vancouver

Techawijittra T, Boriboonhirunsarn D. Rate and Characteristics of Metformin Use in Gestational Diabetes. Obstetrics and Gynecology International. 2026;2026(1). doi:10.1155/ogi/1243724

BibTeX
@article{Techawijittra2026,
  author = {Techawijittra, Thanachot and Boriboonhirunsarn, Dittakarn},
  title = {Rate and Characteristics of Metformin Use in Gestational Diabetes},
  journal = {Obstetrics and Gynecology International},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ogi/1243724}
}
Kostenlos starten →